Alto Neuroscience ANRO Business Segments — Net loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Alto Neuroscience in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Alto Neuroscience’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Alto Neuroscience's business segments — net loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Alto Neuroscience's business segments — net loss?
- Alto Neuroscience (ANRO) reported business segments — net loss of $27.14M in Q1 2026.
- How has Alto Neuroscience's business segments — net loss changed year-over-year?
- Alto Neuroscience's business segments — net loss increased by 73.1% year-over-year, from $15.68M to $27.14M.
- What is the long-term trend for Alto Neuroscience's business segments — net loss?
- Over 2 years (2023 to 2025), Alto Neuroscience's business segments — net loss has grown at a 32.5% compound annual growth rate (CAGR), from $37.81M to $66.36M.
- What does business segments — net loss mean?
- This metric represents the bottom-line financial result for the reportable segment, calculated as total revenues minus all operating expenses and costs. For a clinical-stage biopharmaceutical company, this typically reflects the net cash burn and accounting losses incurred while developing therapeutic assets prior to commercialization. It serves as a primary indicator of the segment's financial performance and the rate at which it consumes capital.